Abstract:Purpose:To evaluate the effect of cisplatin-based peri-operation chemotherapy (CT) on survival after completed resection of non small cell lung cancer (NSCLC)Methods:A prospective, randomized, multicenter study was conducted by Shanghai Lung Cancer Team since Feb 1995 to Dec 2003 for stage Ⅰ~ⅢA NSCLC with completed resection. Patients were randomly assigned to receive pre-operative CT or no pre-operative CT (pre-op CT). Post-operative CT (post-op CT) were used for majority of the patients, except for partial stage I patients. Accumulated survival, log rank, MST, Cox uni-variance and multi-variance analyses, HR were used as statistics for evaluation Results:A total of 337 patients underwent randomization, 169 cases received pre-operative CT, and 168 cases didn't receive pre-operative CT. There was statistical survival difference between the group with no pre-op CT and with pre-op CT, 5-yr survival rate were of 47.85%∶ 36.52%, MST were 56.63∶39.14(P=0.03), respectively. Stage and post-op CT were the only two meaningful parameters with statistical survival difference calculated by multi-variance analyses (P0.01), but no difference was found in others 4 parameters (age, sex, type and pre-op CT). In various stage, a statistical survival difference was only shown in stage Ⅱ NSCLC,(P=0.02), 5-yr survival rate and MST were worse in the group with pre-op CT, 28.50%∶58.91% and 35.38 months∶60 months, respectively, but no difference was seen in stage I and stage ⅢA NSCLC. There was no statistical progression-free survival (PFS) difference between the group with no pre-op CT and with pre-op CT (P=0.10), Stage and post-op CT were two meaningful parameters with statistical PFS difference calculated by multi-variance analyses,HR=2.08 and 0.86, respectively. Stage Ⅱ patients assigned to no pre-op CT had a significantly higher PFS rate than those assigned to pre-op CT (P=0.03), but no difference was seen in stage I and ⅢA NSCLC(P0.05). There were 121 cases received more than 3 cycles post-op CT, 216 cases received less than 3 cycles post-op CT. The patients received more than 3 cycles had better yr-survival and MST than those received less cycles (P=0.04).Post-op CT was not benefit to the survival rate of stage I. In stage Ⅱ and ⅢA ,the patients received ≥3 cycles post-op CT had better yr-survival than those received less cycles(P0.01). From Cox multi-variance analyses, stage and post-op CT were the only two meaningful parameters with statistical survival difference (P0.01). In the cases with pathological ‘T’ down stage and ‘T’ unchanged after pre-op CT had a better yr-survival rate and MST than ‘T’ up-stage, effective chemotherapy might be beneficial to survival. Besides, in the cases with ≥3 cycles of post-op CT have better survival rate than less cycles Conclusions:There was statistical survival difference between the group with no pre-op CT and with pre-op CT in stage I and ⅢA ,but in stage Ⅱ NSCLC, the yr-survival rate was worsen in pre-op CT arm. From multi-variance Cox analyses, more than 3 cycles post-op CT had a better statistical yr-survival than less cycles, more than 3 cycles post-op CT was preferred

Influence of Endostain and Epithelial Growth Factor Receptor on the Survival of the Perioperative No-Small Cell Lung Cancer

[Serum Levels of Endostatin and VEGF in Non-Small Cell Lung Cancer Patients and the Relationship with the Clinical Pathophysiological Characteristics].

Changes And Significance Of Lymphocyte Subsets In Patients With Advanced Nsclc Before And After Endostar Combined Chemotherapy

Comparison of Surgeries Plus Perioperative and Postoperative Chemotherapies in Chinese Pn2 Patients with Non-Small Cell Lung Cancer: A Real-World Observational Study.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Effects of Paclitaxel-Carboplatin (TC) Alone or with Endostatin for Advanced Non-Small Cell Lung Cancer (NSCLC).

Effect of neoadjuvant therapy on serum transforming growth factor-β, squamous cell carcinoma associated antigen, and prognosis in patients with locally advanced esophageal cancer

Expression of PD-L1 and TGF-βin Non-small Cell Lung Cancer and Its Clinical Significance

Surgical Intervention Improves Survival for Metastatic Non-Small Cell Lung Cancer Patients.

The Efficacy and Safety of Extended Use of Endostatin Plus Platinum-Based Doublet Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer: an Analysis of a 10-Year Retrospective Study.

Impact of Anesthetic Factors on Prognosis of Patients with Non-Small Cell Lung Cancer after Surgery

Perioperative Management May Improve Long-term Survival in Patients after Lung Cancer Surgery: A Retrospective Cohort Study

Retrospective study on surgery and post-operative adjuvant treatment in stage Ⅲa non-small cell lung cancer

Prognostic Significance of Preoperative Pulmonary Ventilation Function Test for Postoperative Survival of Patients with Primary Non-small Cell Lung Cancer

Relationship between epidermal growth factor receptor and the prognosis of non-small cell lung cancer

A Review of Biomarkers and Their Clinical Impact in Resected Early-Stage Non-Small-Cell Lung Cancer

Circulating Endothelial Cells and Serum Caspase-Cleaved Ck18 to Predict for Response and Survival in Non-Small Cell Lung Cancer Patients Receiving Endostatin and Paclitaxel-Carboplatin Combined Chemotherapy.

[Survival Analysis of 121 Stage N2-IIIa Non-small Cell Lung Cancer Patients Treated with Surgery].

Study of prognostic predictors for non-small cell lung cancer

A Randomized Study of Peri-Operative Chemotherapy in Patients with Completed Resected Non-Small-cell Lung Cancer

Prognostic factors of patients with small cell lung cancer after surgical treatment

[Investigation of Long-Term Outcome for Lung Cancer of Patients with Neoadjuvant Chemotherapy].